-

Notice of Change of Location of Annual Meeting of Shareholders of PerkinElmer to Be Held on April 28, 2020

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, gave notice today that in response to continued public health restrictions on in-person gatherings given the coronavirus/COVID-19 pandemic, the Board of Directors of PerkinElmer has determined to change the format of the company’s Annual Meeting of Shareholders scheduled for Tuesday, April 28, 2020, at 8:00 a.m. EST from in-person to virtual-only. The meeting will be webcast and can be accessed by stockholders at www.virtualshareholdermeeting.com/PKI2020 using the 16-digit control number on their proxy card, voting instruction form or Notice of Internet Availability. The company has designed the format of the Annual Meeting to ensure that shareholders are afforded the same rights and opportunities to participate as they would at an in-person meeting, using online tools to ensure shareholder access and participation. For additional information regarding accessing and participating in the virtual meeting, please refer to the company’s supplemental proxy materials filed with the Securities and Exchange Commission on April 14, 2020.

As described in the proxy materials for the Annual Meeting, shareholders are entitled to virtually attend and vote at the Annual Meeting only if they held shares as of the close of business on February 28, 2020, the record date designated by the Board for the meeting. Shareholders can continue to vote their shares until 11:59 p.m. Eastern Time on April 27, 2020 at www.proxyvote.com and will be able to access the virtual meeting from the voting website using the 16-digit control number on the proxy card, voting instruction form or notice that was previously mailed or made available to them.

About PerkinElmer

PerkinElmer enables scientists, researchers and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 13,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $2.9 billion in 2019, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Contacts

Media Relations:
Brian Willinsky
(781) 663-5728
brian.willinsky@perkinelmer.com

Investor Relations:
Bryan Kipp
(781) 663-5583
bryan.kipp@perkinelmer.com

PerkinElmer, Inc.

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Versions

Contacts

Media Relations:
Brian Willinsky
(781) 663-5728
brian.willinsky@perkinelmer.com

Investor Relations:
Bryan Kipp
(781) 663-5583
bryan.kipp@perkinelmer.com

More News From PerkinElmer, Inc.

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced it has entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The acquisition is expected to add HCD’s human pancreatic beta cell models to Revvity’s Life Sciences portfolio, supporting drug discovery, screening and preclinical research, including...

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Wednesday, September 9, 2026 8:45 a.m. ET - Prahlad Singh, president and chief executive officer Morgan Stanley 24th Annual Global Healthcare Conference Monday, September 14, 2026 8:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird’s 2026 Global Healthcare Conference Tuesday, September...

Revvity Announces Financial Results for the Second Quarter of 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue for the quarter was $730 million, as compared to $720 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related...
Back to Newsroom